Evidence map›Paper›PMID 32659474›Full record

SynthesisEuropean journal of cancer (Oxford, England : 1990)2020

Genetic variants in TKT and DERA in the nicotinamide adenine dinucleotide phosphate pathway predict melanoma survival.

Ning Gu, Wei Dai, Hongliang Liu, Jie Ge, Sheng Luo, Eunyoung Cho, Christopher I Amos, Jeffrey E Lee, Xin Li, Hongmei Nan and 2 more

Open access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in European journal of cancer (Oxford, England : 1990), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Ning GuJiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, Jiangsu, 210029, China; Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, Jiangsu, 210029, China; Duke Cancer Institute, Duke University Medical Center, Durham, NC, 27710, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, 27710, USA.
Wei DaiDuke Cancer Institute, Duke University Medical Center, Durham, NC, 27710, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, 27710, USA; Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Hongliang LiuDuke Cancer Institute, Duke University Medical Center, Durham, NC, 27710, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, 27710, USA.
Jie GeDuke Cancer Institute, Duke University Medical Center, Durham, NC, 27710, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, 27710, USA.
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, 27710, USA.
Eunyoung ChoDepartment of Dermatology, Warren Alpert Medical School, Brown University, Providence, RI, 02912, USA; Department of Epidemiology, Brown University School of Public Health, Providence, RI, 02912, USA.
Christopher I AmosInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 77030, USA.
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.
Xin LiDepartment of Epidemiology, Fairbanks School of Public Health, Indiana University, Indianapolis, IN, 46202, USA.
Hongmei NanDepartment of Epidemiology, Fairbanks School of Public Health, Indiana University, Indianapolis, IN, 46202, USA.
Hua YuanJiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, Jiangsu, 210029, China; Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, Jiangsu, 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, 210029, China. Electronic address: yuanhua@njmu.edu.cn.
Qingyi WeiDuke Cancer Institute, Duke University Medical Center, Durham, NC, 27710, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA. Electronic address: qingyi.wei@duke.edu.
Duke University · USIndiana University – Purdue University Indianapolis · USBaylor College of Medicine · USBrown University · USNanjing Medical University · CNThe University of Texas MD Anderson Cancer Center · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Genetic Predictors for DNA Repair Phenotype in CMMR01CA100264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, QINGYI · 2004 to 2008
$1.5M
Statistical Methods for Gene Environment Interactions In Lung CancerR01CA133996 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMOS, CHRISTOPHER I. · 2007 to 2009
$790k
NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA014236NCI NIH HHS P50 CA093459NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA100264NCI NIH HHS R01 CA133996NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA186107
6 · The paper itself

Abstract

backgroundCutaneous melanoma (CM) is the most lethal type of skin cancers. Nicotinamide adenine dinucleotide phosphate (NADPH) plays an important role in anabolic reactions and tumorigenesis, but many genes are involved in the NADPH system.

methodsWe used 10,912 single-nucleotide polymorphisms (SNPs) (2018 genotyped and 8894 imputed) in 134 NADPH-related genes from a genome-wide association study (GWAS) of 858 patients from The University of Texas MD Anderson Cancer Center (MDACC) in a single-locus analysis to predict CM survival. We then replicated the results in another GWAS data set of 409 patients from the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS).

resultsThere were 95 of 858 (11.1%) and 48 of 409 (11.7%) patients who died of CM, respectively. In multivariable Cox regression analyses, we identified two independent SNPs (TKT rs9864057 G > A and deoxyribose phosphate aldolase (DERA) rs12297652 A > G) to be significantly associated with CM-specific survival [hazards ratio (HR) of 1.52, 95% confidence interval (CI) = 1.18-1.96, P = 1.06 × 10

conclusionsThese results suggest that these two potentially functional SNPs may be valuable prognostic biomarkers for CM survival, but larger studies are needed to validate these findings.

Indexed as

Polymorphism, Single NucleotideAdultAgedAged, 80 and overAldehyde-LyasesCohort StudiesFemaleFollow-Up StudiesGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMaleMelanomaMetabolic Networks and PathwaysMiddle AgedAldehyde-Lyasesdeoxyribose-phosphate aldolaseNADPTransketolaseCutaneous melanomaGenome-wide association studyMelanoma-specific survivalNicotinamide adenine dinucleotide phosphateSingle-nucleotide polymorphism

Identifiers

PMID32659474
PMCPMC7540967
OpenAlexW3041494976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.